Impact on survival of different treatments for myelodysplastic syndromes (MDS).

[1]  J. Byrd,et al.  Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. , 2007 .

[2]  U. Germing,et al.  Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes , 2007, Cancer.

[3]  G. Mufti,et al.  Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin , 2007, Leukemia.

[4]  G. Mufti,et al.  C025 Low IPSS score and bone marrow hypocellularity in MDS patients predict haematological responses to anti-thymocyte globulin , 2007 .

[5]  R. Fanin,et al.  P144 Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS) , 2007 .

[6]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[7]  P. Musto,et al.  Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. , 2006, Leukemia research.

[8]  C. Steidl,et al.  P-112 Results of a phase II trial with valproic acid (VPA) alone or in combination with all-trans-retinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS , 2005 .

[9]  J. Issa,et al.  P-119 Advanced myelodysplastic syndromes (MDS): Patient subset results of a phase III trial comparing decitabine (DAC) vs. supportive care (SC) , 2005 .

[10]  U. Germing,et al.  Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.

[11]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[12]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  U. Germing,et al.  Thalidomide for the treatment of patients with myelodysplastic syndromes , 2002, Leukemia.

[14]  P. Venugopal,et al.  Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.

[15]  U. Germing,et al.  Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.

[16]  J. Bennett,et al.  World Health Organization classification of the acute leukemias and myelodysplastic syndrome. , 2000, International journal of hematology.

[17]  F. Appelbaum,et al.  Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. , 1998, Leukemia.

[18]  M. Labopin,et al.  Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome , 1998, Bone Marrow Transplantation.

[19]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[20]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.